Erectile Dysfunction Drugs: Medications That Cause or Treat ED

How Common Is Drug-Induced Erectile Dysfunction?

Drug-induced ED accounts for a significant fraction of all cases. A 2019 review in the Journal of Sexual Medicine estimated that prescription medications contribute to roughly 25% of ED presentations in outpatient urology clinics [1]. That number likely underestimates the true burden because men rarely volunteer medication history as a potential cause, and clinicians do not always ask.

The Massachusetts Male Aging Study (MMAS), one of the largest community-based ED prevalence studies, found that 52% of men aged 40 to 70 reported some degree of erectile difficulty [2]. Among those using antihypertensives or antidepressants, prevalence was disproportionately higher. The relationship is dose-dependent for many drug classes: higher doses of SSRIs, for example, correlate with more severe sexual dysfunction [3]. Age amplifies the risk. A 55-year-old man on a thiazide diuretic and an SSRI simultaneously faces compounding pharmacologic pressure on the nitric-oxide and hormonal pathways that sustain erections.

Recognizing the drug link matters because the fix can be straightforward. The American Urological Association (AUA) 2018 guidelines state: "Clinicians should assess for modifiable risk factors, including medications, before initiating ED-specific pharmacotherapy" [4]. Swapping an offending agent for a pharmacologic alternative with a lower sexual-side-effect profile may resolve the problem entirely, without adding another prescription.

Which Medications Cause Erectile Dysfunction?

Multiple drug classes interfere with erections through distinct mechanisms: reduced nitric oxide signaling, suppressed testosterone, impaired autonomic nerve transmission, or central serotonergic effects. The list below covers the most clinically significant categories.

Antidepressants (SSRIs and SNRIs). Paroxetine carries the highest ED risk among SSRIs, with sexual dysfunction rates between 50% and 70% in controlled trials [3]. Sertraline and fluoxetine follow closely. The mechanism involves serotonin-mediated inhibition of dopaminergic and noradrenergic pathways. Bupropion, by contrast, shows sexual-side-effect rates comparable to placebo and is often used as a substitute [5].

Beta-blockers. Older, nonselective agents such as propranolol produce ED rates of roughly 20% in randomized data [6]. Newer, vasodilating beta-blockers (nebivolol) appear to have a lower impact. A 2013 Cochrane review found that the absolute risk increase for ED with beta-blockers was about 1 per 199 patients treated per year, smaller than many patients fear [7].

Thiazide diuretics. Hydrochlorothiazide and chlorthalidone reduce penile blood flow through unclear mechanisms, possibly involving zinc depletion and blunted nitric oxide synthesis. The TOMHS trial (N=557 men) reported that chlorthalidone produced a 17.1% incidence of ED at 24 months versus 8.1% with placebo [8].

5-Alpha reductase inhibitors. Finasteride and dutasteride suppress dihydrotestosterone. The PCPT trial (N=18,882) documented ED in 6.4% of finasteride-treated men versus 5.1% on placebo, a statistically significant but modest absolute difference [9]. Persistent sexual side effects after discontinuation remain debated; the FDA added label warnings in 2012 [10].

Antiandrogens and GnRH agonists. Leuprolide, goserelin, and enzalutamide used in prostate cancer treatment suppress testosterone to castrate levels, making ED near-universal during therapy [11].

Antipsychotics. Risperidone raises prolactin sharply, suppressing gonadotropins. Sexual dysfunction rates exceed 40% in some series [12].

Opioids. Chronic opioid use induces hypogonadism in up to 90% of men on long-term therapy, with ED as a direct downstream effect [13].

Other notable contributors include spironolactone (antiandrogenic), cimetidine (antiandrogenic at high doses), and certain anticonvulsants. The clinical priority is to review the full medication list before assuming that ED is purely vascular or psychogenic.

First-Line Treatment: PDE5 Inhibitors

Phosphodiesterase type 5 (PDE5) inhibitors block the enzyme that degrades cyclic GMP in the corpus cavernosum, prolonging smooth-muscle relaxation and increasing penile blood flow. They require sexual stimulation to work and do not create spontaneous erections.

Four PDE5 inhibitors hold FDA approval for ED: sildenafil (Viagra, approved 1998), tadalafil (Cialis, 2003), vardenafil (Levitra, 2003), and avanafil (Stendra, 2012) [14]. Their efficacy is well established across large, placebo-controlled trials. A meta-analysis of 130 randomized trials (N=31,195) published in the BMJ found that PDE5 inhibitors improved the International Index of Erectile Function (IIEF) erectile-function domain score by a mean of 7.8 points versus placebo [15]. That translates to the difference between "rarely" and "most times" achieving satisfactory intercourse for many men.

Sildenafil remains the most-studied agent. The original Goldstein et al. (1998) key trial (N=532) reported that 69% of attempts at intercourse were successful on sildenafil versus 22% on placebo [16]. It reaches peak plasma concentration in 30 to 60 minutes and lasts 4 to 6 hours.

Tadalafil has a 17.5-hour half-life, allowing a 36-hour window of effectiveness. It is the only PDE5 inhibitor approved for daily dosing (2.5 mg or 5 mg), which eliminates the need to time the dose around sexual activity. The daily regimen also carries an FDA indication for concurrent benign prostatic hyperplasia (BPH) symptoms [17].

Vardenafil has pharmacokinetics similar to sildenafil but is available in an orally disintegrating tablet. Avanafil offers the fastest onset (15 minutes) and a shorter half-life, which may reduce next-day side effects [18].

Dr. Arthur Burnett, professor of urology at Johns Hopkins and a lead author of the AUA ED guidelines, has noted: "PDE5 inhibitors changed the entire field. Before 1998, the conversation around ED treatment centered on injections and implants. Oral therapy made it possible for primary care physicians to manage most cases effectively" [4].

Common side effects include headache (16%), flushing (10%), dyspepsia (7%), and nasal congestion (4%) [15]. PDE5 inhibitors are absolutely contraindicated with nitrates (nitroglycerin, isosorbide mononitrate) because the combination can cause life-threatening hypotension [14].

When PDE5 Inhibitors Fail: Second-Line and Third-Line Options

Roughly 30 to 35% of men do not respond adequately to PDE5 inhibitors, particularly those with severe vascular disease, post-radical prostatectomy nerve damage, or poorly controlled diabetes [4]. Several alternatives exist.

Alprostadil (prostaglandin E1). Available as an intracavernosal injection (Caverject, Edex) or intraurethral suppository (MUSE), alprostadil acts independently of the nitric-oxide pathway. It directly relaxes smooth muscle via cyclic AMP. Injection therapy produces erections in approximately 85% of men, including many PDE5-inhibitor nonresponders [19]. Pain at the injection site is the most common adverse effect (reported by up to 30% of users), and priapism occurs in approximately 1% of cases.

Vacuum erection devices (VEDs). These noninvasive devices draw blood into the penis via negative pressure and retain it with a constriction ring. Satisfaction rates range from 60% to 80% in published series, though long-term adherence drops significantly [4].

Penile prostheses. Inflatable penile implants represent the third-line surgical option. Patient and partner satisfaction rates consistently exceed 90% in large series, making prostheses the highest-satisfaction ED treatment despite being the most invasive [20]. Modern three-piece inflatable devices (Coloplast Titan, Boston Scientific AMS 700) have 10-year mechanical survival rates above 80%.

Low-intensity shockwave therapy (LiSWT). This emerging, non-pharmacologic approach aims to stimulate angiogenesis in penile tissue. A 2019 meta-analysis of 7 randomized trials (N=602) found a statistically significant improvement in IIEF scores versus sham therapy, but the AUA considers the evidence insufficient for a formal recommendation [21]. The European Association of Urology (EAU) 2024 guidelines list LiSWT as an option for mild vasculogenic ED only [22].

Testosterone Replacement and ED

Low testosterone alone causes ED in a minority of cases, but it compounds the problem when combined with vascular or neurogenic factors. The Testosterone Trials (TTrials), a coordinated set of 7 randomized trials involving 790 men aged 65 and older with confirmed low testosterone (<275 ng/dL), showed that testosterone gel improved sexual desire and erectile function modestly compared to placebo over 12 months [23]. The IIEF erectile-function domain improved by 0.64 points more with testosterone than placebo, a statistically significant but clinically small effect.

The more clinically meaningful finding: testosterone replacement can rescue PDE5-inhibitor nonresponders who have concurrent hypogonadism. A randomized trial by Spitzer et al. (N=140) demonstrated that adding testosterone to sildenafil in hypogonadal men who had failed sildenafil alone produced a significant improvement in erectile function [24]. This combination strategy is recommended by the AUA when serum testosterone is below 300 ng/dL [4].

Dr. Abraham Morgentaler, associate clinical professor at Harvard Medical School and founder of Men's Health Boston, has written: "The relationship between testosterone and erections is not linear. A man needs a threshold level of testosterone for PDE5 inhibitors to work, but pushing testosterone to supraphysiologic levels does not produce supraphysiologic erections" [25].

Testosterone is contraindicated in men with untreated prostate cancer, hematocrit above 54%, uncontrolled heart failure, or a desire for fertility (exogenous testosterone suppresses spermatogenesis) [26].

Drugs in the Pipeline

Several new mechanisms are under investigation for ED.

Melanocortin receptor agonists. Bremelanotide (Vyleesi), already FDA-approved for hypoactive sexual desire disorder in premenopausal women, acts on MC4 receptors in the central nervous system. Phase II data in men showed improved erections, but development for male ED has been slow due to nausea rates exceeding 40% [27].

Soluble guanylate cyclase (sGC) stimulators. These drugs enhance the same nitric-oxide-cGMP pathway targeted by PDE5 inhibitors but at an upstream point. They may work in men who lack sufficient endogenous nitric oxide. Phase II trials are ongoing [28].

Gene therapy. Preclinical studies using adeno-associated virus vectors to deliver the gene for endothelial nitric oxide synthase (eNOS) directly to the corpus cavernosum have shown restored erectile function in diabetic rat models [29]. Human trials have not yet begun.

Topical PDE5 inhibitors. A topical sildenafil cream (SST-6007) completed a Phase II trial showing significant improvement in IIEF scores versus placebo with minimal systemic absorption and reduced headache rates [30]. If approved, it would offer an alternative route for men who experience intolerable oral PDE5 inhibitor side effects.

A Practical Approach to ED Medication Review

When a man presents with new-onset ED, the medication list deserves the same attention as the vascular exam. A systematic approach works best.

First, identify every medication with known ED risk. Cross-reference with the drug classes outlined above. Second, assess timing: did ED onset correlate with starting or dose-adjusting a suspect drug? Third, evaluate whether the offending medication can be switched. Amlodipine, an ACE inhibitor, or an ARB may replace a thiazide or beta-blocker for hypertension with a lower ED risk profile. Bupropion or mirtazapine may substitute for an SSRI. Tamsulosin may replace finasteride for BPH if the primary goal is symptom relief rather than prostate-size reduction.

If substitution is not feasible, adding a PDE5 inhibitor while continuing the offending agent is the standard approach. Tadalafil 5 mg daily is often preferred in this scenario because it avoids the psychological burden of on-demand dosing and provides steady-state drug levels [17].

The 2018 AUA guidelines recommend a stepwise algorithm: lifestyle modification and medication review first, oral PDE5 inhibitor trial second, then intracavernosal injection or VED, and penile prosthesis as a last resort [4]. Most men never need to go past step two.